Published in Cancer Manag Res on August 17, 2010
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma | NCT00949702
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma (F5) | NCT00910650
Clinical Trial of Sutent to Treat Metastatic Melanoma | NCT00631618
Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255) | NCT00424515
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma | NCT00577382
Trial of Imatinib (Gleevec®) in Selected Patients With Metastatic Melanoma | NCT00881049
Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov (2011) 1.07
Novel biomarkers and therapeutic targets for optimizing the therapeutic management of melanomas. World J Clin Oncol (2012) 0.94
Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. Onco Targets Ther (2011) 0.88
Gene therapy for advanced melanoma: selective targeting and therapeutic nucleic acids. J Drug Deliv (2013) 0.84
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. Br J Cancer (2015) 0.78
Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery. Clinicoecon Outcomes Res (2012) 0.78
Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg (2012) 0.78
New Perspectives of "omics" Applications in Melanoma Research. Open Biochem J (2011) 0.77
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients. J Hematol Oncol (2017) 0.75
Partial hepatectomy for primary hepatic melanoma: a report of two cases and review of the literature. World J Surg Oncol (2014) 0.75
Two cases of partial hepatectomy for malignant melanoma. Hawaii J Med Public Health (2012) 0.75
Controversies in the diagnosis and treatment of early cutaneous melanoma. J Med Life (2015) 0.75
Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds? Cancer Manag Res (2015) 0.75
Apoptosis and injuries of heavy ion beam and x-ray radiation on malignant melanoma cell. Exp Biol Med (Maywood) (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
Distinct sets of genetic alterations in melanoma. N Engl J Med (2005) 17.26
Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 15.64
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13
Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg (1992) 9.97
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol (2009) 6.44
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol (1999) 5.95
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res (2007) 5.51
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (2005) 5.36
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg (1997) 4.47
Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet (1998) 4.46
Increasing burden of melanoma in the United States. J Invest Dermatol (2009) 4.43
Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann Surg (1998) 4.35
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
Excision margins in high-risk malignant melanoma. N Engl J Med (2004) 3.94
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol (2000) 3.42
Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet (1995) 3.03
Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol (2008) 2.88
Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (1986) 2.84
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer (1982) 2.71
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol (2009) 2.63
Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol (2006) 2.60
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol (2004) 2.36
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28
The orderly progression of melanoma nodal metastases. Ann Surg (1994) 2.16
Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl J Med (1988) 2.15
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol (2007) 1.90
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am (2006) 1.89
Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol (1998) 1.82
Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer (2003) 1.80
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol (2007) 1.79
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer (2006) 1.75
Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol (2008) 1.61
Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg (1991) 1.52
Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol (2003) 1.52
Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol (2006) 1.50
A comparison of survival rates for treatment of melanoma metastatic to the brain. Cancer Invest (2004) 1.46
Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc (1986) 1.44
Melanoma. J Natl Compr Canc Netw (2009) 1.37
Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res (2008) 1.29
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. Ann Oncol (2006) 1.29
A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer (1989) 1.27
Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery (2001) 1.26
Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys (2004) 1.25
Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery (1994) 1.23
Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys (1998) 1.22
Total synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical development. Angew Chem Int Ed Engl (2006) 1.20
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol (1995) 1.20
Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia (1996) 1.18
Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol (2002) 1.15
Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg (2001) 1.14
Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics. Ann N Y Acad Sci (2005) 1.13
Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol (2002) 1.10
Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol (2007) 1.08
Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst (1995) 1.08
Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys (2002) 1.07
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist (2008) 1.05
The classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classification. Pathology (1986) 1.05
Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials Group. Eur J Cancer (1994) 1.05
A phase II study of taxol in patients with malignant melanoma. Invest New Drugs (1991) 1.04
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res (2002) 1.03
Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm). Cancer (2009) 1.03
Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer (2004) 1.01
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma. J Clin Oncol (2009) 1.01
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer (2003) 1.00
Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. Arch Surg (2004) 0.98
Cyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progression. J Biol Chem (2006) 0.98
Surgical margins and prognostic factors in patients with thick (>4mm) primary melanoma. Ann Surg Oncol (1998) 0.98
Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg (2002) 0.97
Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions. Arch Surg (1995) 0.96
Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma. J Immunother (2009) 0.95
Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases. Neuro Oncol (2008) 0.95
Differential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophages. Cancer Res (1989) 0.91
Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol (2008) 2.35
Removing the unknown from the carcinoma of unknown primary. J Clin Oncol (2012) 1.99
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A (2013) 1.88
Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res (2005) 1.65
Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem (2004) 1.43
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors. Cancer Control (2007) 1.32
Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr (2011) 1.15
In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates. Mol Cancer Ther (2005) 1.11
Activated stat-3 in melanoma. Cancer Control (2008) 1.11
Src activation in melanoma and Src inhibitors as therapeutic agents in melanoma. Melanoma Res (2009) 1.02
Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. J Clin Oncol (2004) 0.97
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta. Clin Cancer Res (2005) 0.94
Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control (2006) 0.92
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest (2016) 0.89
Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies. Clin Cancer Res (2007) 0.89
An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second 'primary' tumor. J Cutan Pathol (2011) 0.85
Immunotherapy as part of a multidisciplinary approach to melanoma treatment. Front Biosci (2006) 0.84
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res (2011) 0.83
State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer. Cancer (2008) 0.80
PD-1 and PD-L1 antibodies for melanoma. Hum Vaccin Immunother (2014) 0.80
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs (2015) 0.78
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs (2011) 0.77
NRAS-mutant melanoma: response to chemotherapy. Arch Dermatol (2011) 0.77
New horizons in melanoma treatment: targeting molecular pathways. Ochsner J (2010) 0.76
BEAM trial: lighting the way ahead? J Clin Oncol (2011) 0.75
Reply to M.-E. Percival et al and L.B. Saltz. J Clin Oncol (2013) 0.75
Melanoma: promising new discoveries and treatment modalities for difficult clinical scenarios. Cancer Control (2008) 0.75